InMed Pharmaceuticals Inc.
Organization details
- Legal name
- InMed Pharmaceuticals Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- British Columbia, Canada
- Headquarters city
- Vancouver
- Headquarters country
- Canada
- Fiscal year end
- June
- Ticker symbol
- INM
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001728328
Board of directors
-
Andrew Hull · DirectorSince 2023
-
Bryan T. Baldasare · DirectorSince 2023
-
Eric A. Adams · Director · President & CEOSince 2023
-
Janet P. Grove · DirectorSince 2023
-
John Steven Bathery · DirectorSince 2025
-
Neil A. Klompas · DirectorSince 2024
-
Nicole Lemerond · DirectorSince 2023
Chief executives
Board connections
1 of this board's directors also sit on 2 other boards. 2 are in the same sector.
-
GeoVax Labs Inc. Same sectorvia Nicole Lemerond
-
Medicinova Inc Same sectorvia Nicole Lemerond
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $1,382,430
- 47 purchases by 4 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 5, 2026 | ADAR1 Capital Management, LLC 10% owner | Open-market purchase | +2,640 | $13.10 | $34,572 |
| Oct 23, 2026 | ADAR1 Capital Management, LLC 10% owner | Open-market purchase | +4 | $1.32 | $5 |
| Oct 19, 2026 | ADAR1 Capital Management, LLC 10% owner | Open-market purchase | +1,086 | $1.32 | $1,434 |
| Oct 16, 2026 | ADAR1 Capital Management, LLC 10% owner | Open-market purchase | +1 | $1.32 | $1 |
| Oct 8, 2026 | ADAR1 Capital Management, LLC 10% owner | Open-market purchase | +2,256 | $1.33 | $2,997 |
| Oct 7, 2026 | ADAR1 Capital Management, LLC 10% owner | Open-market purchase | +3,046 | $1.33 | $4,051 |
| Oct 6, 2026 | ADAR1 Capital Management, LLC 10% owner | Open-market purchase | +5,601 | $1.33 | $7,436 |
| Oct 5, 2026 | ADAR1 Capital Management, LLC 10% owner | Open-market purchase | +18,182 | $1.33 | $24,182 |
| Oct 2, 2026 | ADAR1 Capital Management, LLC 10% owner | Open-market purchase | +8,307 | $1.33 | $11,048 |
| Oct 1, 2026 | ADAR1 Capital Management, LLC 10% owner | Open-market purchase | +16,431 | $1.33 | $21,850 |
| Sep 16, 2026 | Schneeberger Daniel 10% owner | Open-market purchase | +8,340 | $1.29 | $10,759 |
| Sep 15, 2026 | Schneeberger Daniel 10% owner | Open-market purchase | +54,256 | $1.30 | $70,533 |
| Sep 14, 2026 | Schneeberger Daniel 10% owner | Open-market purchase | +28,505 | $1.29 | $36,771 |
| Jul 16, 2026 | Vivo Opportunity Cayman Fund, L.P. 10% owner | Open-market purchase | +19 | $1.55 | $29 |
| Jul 16, 2026 | Vivo Opportunity Cayman Fund, L.P. 10% owner | Open-market purchase | +2 | $1.55 | $3 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about InMed Pharmaceuticals Inc.
Who is the CEO of InMed Pharmaceuticals Inc.?
Eric A. Adams is InMed Pharmaceuticals Inc.'s President & CEO.
How many directors are on InMed Pharmaceuticals Inc.'s board?
InMed Pharmaceuticals Inc.'s board has 7 directors: Andrew Hull, Bryan T. Baldasare, Eric A. Adams, Janet P. Grove, John Steven Bathery, Neil A. Klompas and Nicole Lemerond.
Are InMed Pharmaceuticals Inc. insiders buying or selling shares?
Over the last 12 months, InMed Pharmaceuticals Inc. insiders bought $1.4 million of shares in 47 purchases and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="inmed-pharmaceuticals-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.